Brands of Ceftriaxone in Kenya
Accuzon®, Macleods Pharmaceuticals Limited
Auroxone®, Aurobindo Pharma Ltd
Axone®, Cadila Pharmaceuticals (EA) Ltd
Ceftriaxone®, Yeluri Formulations Pvt.ltd.
Ceftrimed®, Medisel Kenya Ltd
Ceftrisone®, Unosource Pharma Limited
Ceftron®, Square Pharmaceuticals Ltd.
Cefzona®, Careplus Ltd
Cetafor®, Dafra Pharma GmbH
Da-Oxone®, Dawa Limited
Desefin®, Pharmaco Healthcare Limited
Eracef®, Brawn Laboratories Ltd.
Eracef®,Popular Pharmaceuticals Ltd.
Enoxirt®, Julphar Pharmaceutical industries
Esszone®,Essar K ltd
G-Ceftria®, Guilin Pharmaceutical Co. Ltd.
Iffibact®, Inject Care Parenterals Pvt.ltd.
Imaxone®, Makcur Laboratories Ltd
Injxone®, Inject Care Parenterals Pvt.ltd.
Inno-Ceft®, Innocia Lifesciences Pvt. Ltd.
Kricef® , Krishna Chemists Ltd
Mesporin®,Acino Pharma Ag
Monotax®, Zydus Healthcare Limited
Nectram® , Nectar Lifesciences Limited
Nexozone®, Innova Cap Tab Pvt. Ltd,
Nirixone® ,Aculife Healthcare Pvt Ltd
Onecef®, Zawadi Healthcare Ltd
Padex®, Gufic Stridden Biopharma Private Ltd.
Pancef-O®, Aglowmed Limited
Powercef®, Wochhardt Limited
Radicef®, Radiant Pharmaceuticals Ltd.
Rocephin®,F. Hoffman-LA Roche Ltd
Samixon®, Hikma pharmaceuticals Ltd
Supraxone®, Zhuhai United Laboratories (Zhongshan) Co. Ltd
Theotaz®, Theon Pharmaceuticals Ltd
Traxef®,CCL Pharma (pvt) Ltd
Trixon®, Lincoln Pharmaceuticals Ltd
Triaxone®, Lab and Allied
Trox®, Laborate Pharmaceuticals India Limited
Zefone®, Zydus Cadila Healthcare Limited
Zoxon®, sanofi-aventis Kenya
Ceftriaxone Mechanism of Action
Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Mechanism of Resistance
Resistance to ceftriaxone is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.
Lower Respiratory Tract Infections: caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens.
Acute bacterial otitis media: caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains).
Skin and skin structure infections: caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii,* Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species.
Urinary tract infections (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae.
Uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae.
Pelvic inflammatory disease: caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added.
Bacterial septicemia :caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae.
Bone and joint infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species.
Intra-abdominal infections: caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species.
Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and Escherichia coli.
Surgical prophylaxis: The preoperative administration of a single 1 g dose of Ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although Ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery.
Ceftriaxone is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone
Premature neonates: Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).
Hyperbilirubinemic neonates: Hyperbilirubinemic neonates should not be treated with ceftriaxone. Ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients.
Neonates Requiring Calcium Containing IV Solutions
Ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium
Intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.
- Ceftriaxone will increase level or effect of argatroban by anticoagulation.
ceftriaxone decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- Do not use ANY calcium containing solutions (including Ringer or Harmann solutions) in combination with IV ceftriaxone; risk of potentially fatal particulate precipitation in lungs, kidneys. Separate by at least 48 hrs.
- Ceftriaxone will increase the level or effect of bivalirudin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity
- Ceftriaxone decreases effects of BCG vaccine live by pharmacodynamic antagonism.
- Ceftriaxone increases effects of dalteparin by anticoagulation. Avoid or Use Alternate Drug. Cephalosporins may decrease prothrombin activity.
- Ceftriaxone increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity.
- Ceftriaxone will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora.
- Chloramphenicol decreases effects of ceftriaxone by pharmacodynamic antagonism.
- Tetracyclines (Doxycycline, Minocycline, Tigecycline, Demeclocycline, Tetracycline) decreases effects of ceftriaxone by pharmacodynamic antagonism.
- Ceftriaxone increases toxicity of furosemide by pharmacodynamic synergism.
ADVERSE DRUG REACTIONS
Gastrointestinal – pancreatitis, stomatitis and glossitis.
Genitourinary – oliguria, ureteric obstruction, post-renal acute renal failure.
Dermatologic – exanthema, allergic dermatitis, urticaria, edema; acute generalized exanthematous pustulosis (agep) and isolated cases of severe cutaneous adverse reactions (erythema multiforme, stevens-johnson syndrome or lyell’s syndrome/toxic epidermal necrolysis) have been reported.
Hematological changes: isolated cases of agranulocytosis (< 500/mm3) have been reported, most of them after 10 days of treatment and following total doses of 20 g or more.
Nervous system disorders: convulsion
Other, adverse reactions: symptomatic precipitation of ceftriaxone calcium salt in the gallbladder, kernicterus, oliguria, and anaphylactic or anaphylactoid reactions.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, firstname.lastname@example.org or clicking below button:
Ceftriaxone in Kenya
Cost of Ceftriaxone Injection in Kenya
Ceftriaxone Side Effects
uses of Ceftriaxone in Kenya
Ceftriaxone in Kenya
Ceftriaxone in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: Intravenous, intramuscular
Protein Binding: Not Available
Onset of Action: Not Available
Elimination Half life: 5.8–8.7 hours
Excretion: 33–67% kidney, 35–45% biliary
Legal Status | Dosage forms & Strengths
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
|CompTox Dashboard (EPA)|
- PPB Drugs Retention Register
- Richards, D. M., et al. “Ceftriaxone.” Drugs 27.6 (1984): 469-527.
- Patel, I. H., et al. “Pharmacokinetics of ceftriaxone in humans.” Antimicrobial Agents and Chemotherapy 20.5 (1981): 634-641.
- Cleeland, R., and E. Squires. “Antimicrobial activity of ceftriaxone: a review.” The American journal of medicine 77.4C (1984): 3.